Clinical Trials Directory

Trials / Completed

CompletedNCT00036751

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

A Phase II Trial Of STI571 For The Treatment Of Platinum And Taxane Refractory Stage III And IV Epithelial Ovarian Cancer And Primary Peritoneal Cancer

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
Female
Age
—
Healthy volunteers
Not accepted

Summary

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer that has not responded to previous treatment. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth

Detailed description

OBJECTIVES: I. Determine the response rates (confirmed, complete, and partial) in patients with platinum- and taxane-refractory stage III or IV ovarian epithelial or primary peritoneal cancer treated with imatinib mesylate. II. Determine the toxicity of this drug in these patients. III. Correlate, preliminarily, CD117 and platelet-derived growth factor receptor expression levels with response in patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGimatinib mesylateGiven orally
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2002-04-01
Primary completion
2007-08-01
First posted
2003-01-27
Last updated
2013-01-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00036751. Inclusion in this directory is not an endorsement.